Focus sur l'empagliflozine. Synthese des analyses post hoc de l'etude cardiovasculaire empa-reg outcome.

Scheen, André

Download

Article (Scientific journals)

Focus sur l'empagliflozine. Synthese des analyses post hoc de l'etude cardiovasculaire empa-reg outcome.

Scheen, André

2019 • In Revue Médicale de Liège, 74 (4), p. 185-191

Peer reviewed

Permalink
https://hdl.handle.net/2268/235350

PubMed
30997967

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

201904_04.pdf

Publisher postprint (309.38 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Empagliflozin; Heart failure; Mortality; SGLT; Type 2 diabetes; 2 inhibitor; Cardiovascular risk

Abstract :

[en] EMPA-REG OUTCOME trial studied the cardiovascular safety of empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, compared to placebo, in patients with type 2 diabetes and high cardiovascular risk. It showed a significant reduction of major cardiovascular events (-14 %), cardiovascular mortality (-38 %), all-cause death (-32 %), hospitalisations for heart failure (-35 %) and progression of renal disease (-39 %). This article proposes an update, almost 4 years after the original publication, of recent post hoc analyses of this landmark study.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

Focus sur l'empagliflozine. Synthese des analyses post hoc de l'etude cardiovasculaire empa-reg outcome.

Alternative titles :

[en] Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME

Publication date :

2019

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

185-191

Peer reviewed :

Peer reviewed

Available on ORBi :

since 10 May 2019

Statistics

Number of views

161 (5 by ULiège)

Number of downloads

96 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Zinman B, Wanner C, Lachin JM, et al.- Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015, 373, 2117-2128.
Scheen AJ.- Etudes cardiovasculaires chez le patient diabétique de type 2 à risque: conclusions et impact des essais publiés en 2017-2018. Médecine des maladies Métaboliques, 2019, 13, S10-S24.
Zelniker TA, Wiviott SD, Raz I, et al.-SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, 2019, 393, 31-39.
Davies MJ, D'Alessio DA, Fradkin J, et al.-Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018, 61, 2461-2498.
Scheen AJ, Paquot N.- Prise en charge de l'hyperglycémie du diabète de type 2: changement de paradigme selon le consensus ADA-EASD 2018. Rev Med Liege, 2018, 73, 629-633.
Cosentino F, Ceriello A, Baeres FMM, et al.-Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. Eur Heart J, 2018, Nov 16. doi: 10.1093/eurheartj/ehy677. [Epub ahead of print].
Scheen AJ.- EMPA-REG OUTCOME. L'empagliflozine réduit la mortalité chez le patient diabétique de type 2 à haut risque cardiovasculaire. Rev Med Liege, 2015, 70, 583-589.
Zinman B, Inzucchi SE, Lachin JM, et al.-Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke, 2017, 48, 1218-1225.
Scheen AJ.- Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes Metab, 2016, 42, 71-76.
Kaul S.- Is the mortality benefit with empagliflozin in type 2 diabetes mellitus too good to be true ? Circulation, 2016, 134, 94-96.
Fitchett D, Inzucchi SE, Lachin JM, et al.- Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J Am Coll Cardiol, 2018, 71, 364-367.
Claggett B, Lachin JM, Hantel S, et al.- Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease. Circulation, 2018, 138, 1599-1601.
Fitchett D, Zinman B, Wanner C, et al.- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J, 2016, 37, 1526-1534.
Savarese G, Sattar N, Januzzi J, et al.- Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality. Circulation, 2019, 139, 1458-1460.
Januzzi J, Ferreira JP, Bohm M, et al.- Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. Eur J Heart Fail, 2019, 21, 386-388.
Fitchett D, Butler J, van de Borne P, et al.- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J, 2018, 39, 363-370.
Wanner C, Inzucchi SE, Lachin JM, et al.-Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med, 2016, 375, 323-334.
Scheen AJ, Piérard L, Krzesinski J-M, et al.-Protection cardiovasculaire et rénale du patient diabétique de type 2: le point après EMPA-REG OUTCOME et LEADER. Rev Med Liege, 2016, 71, 376-381.
Wanner C, Heerspink HJL, Zinman B, et al.-Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J Am Soc Nephrol, 2018, 29, 2755-2769.
Wanner C, Lachin JM, Inzucchi SE, et al.-Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation, 2018, 137, 119-129.
Zinman B, Inzucchi SE, Wanner C, et al.-Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME(R). Diabetologia, 2018, 61, 1522-1527.
Verma S, Mazer CD, Fitchett D, et al.- Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia, 2018, 61, 1712-1723.
Verma S, Mazer CD, Bhatt DL, et al.- Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial. Diabetes Care, 2019, 42, e42-e44.
Verma S, Mazer CD, Al-Omran M, et al.- Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation, 2018, 137, 405-407.
Salsali A, Kim G, Woerle HJ, et al.- Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. Diabetes Obes Metab, 2016, 18, 1034-1040.
Fitchett D, Inzucchi SE, Cannon CP, et al.- Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation, 2019, 139, 1384-1395.
Scheen AJ.- Reappraisal of the diuretic effect of empagliflozin in EMPA-REG OUTCOME: comparison with classic diuretics. Diabetes Metab, 2016, 42, 224-233.
Scheen AJ.- Historique des études cardiovasculaires: de l'UGDP … aux dernières études. Médecine des maladies Métaboliques, 2017, 11, 2S15-12S26.
Scheen AJ.- Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract, 2016, 121, 204-214.
Inzucchi SE, Kosiborod M, Fitchett D, et al.-Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation, 2018, 138, 1904-1907.
Inzucchi SE, Zinman B, Fitchett D, et al.- How does empagliflozin reduce cardiovascular mortality ? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care, 2018, 41, 356-363.
Scheen AJ.- Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res, 2018, 122, 1439-1459.
Bonnet F, Scheen AJ.- Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease. Diabetes Metab, 2018, 44, 457-464.
Inzucchi SE, Wanner C, Hehnke U, et al.-Retinopathy outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. Diabetes Care, 2019, 42, e53-e55.
Sattar N, Fitchett D, Hantel S, et al.- Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia, 2018, 61, 2155-2163.
Scheen AJ.- Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications. Diabetes Metab, 2019, Jan 29. pii: S1262-3636(19)30023-0. doi: 10.1016/j.diabet.2019.01.008. [Epub ahead of print].